News | July 10, 2023
Thermo Fisher Scientific to acquire CorEvitas for $912.5 million
Advances clinical research capabilities with leading regulatory grade registries platform
Advances clinical research capabilities with leading regulatory grade registries platform
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
_256_384.jpg)
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
Subscribe To Our Newsletter & Stay Updated
